Kenneth Wong
About Kenneth Wong
Kenneth Wong is a Scientist I in Pharmacology & Toxicology at CytomX Therapeutics, where he has worked since 2019. He specializes in evaluating probody molecules for cancer immunotherapy and coordinates pharmacokinetic studies with external vendors.
Work at CytomX Therapeutics
Kenneth Wong has been employed at CytomX Therapeutics since 2015, progressing through various roles. He currently serves as Scientist I in the Pharmacology & Toxicology department, a position he has held since 2019. In this role, he facilitates the scheduling and design of in vivo studies and coordinates non-human primate pharmacokinetic studies with outside vendors. Prior to his current position, he worked as an Associate Scientist from 2015 to 2019 and as a Senior Research Associate from 2012 to 2015, contributing to the evaluation of probody molecules and drug conjugates.
Education and Expertise
Kenneth Wong has an extensive educational background in the sciences. He earned a Bachelor of Science in Chemistry from the University of California, Berkeley, studying from 1972 to 1974. He later obtained a Master of Science in Chemistry from San Francisco State University, where he studied from 1978 to 1983. Additionally, he holds a Master of Arts in Cell and Molecular Biology from San Francisco State University, achieved between 1990 and 1994, and a Master of Arts in Theology from Fuller Theological Seminary, completed from 1980 to 1983.
Background
Kenneth Wong has built a career in pharmacology and toxicology, primarily at CytomX Therapeutics in South San Francisco. His work focuses on cancer immunotherapy, specifically evaluating probody molecules and drug conjugates. Wong has supervised research associates and has been involved in various in vivo studies utilizing mouse xenograft models to assess efficacy and pharmacokinetics.
Achievements
Throughout his career at CytomX Therapeutics, Kenneth Wong has contributed to significant research in pharmacology and toxicology. His expertise includes the design and execution of in vivo studies and the coordination of complex pharmacokinetic studies. Wong's work in evaluating probody molecules has implications for advancing cancer treatment options.